Soleno Therapeutics' Study Outcome Bolsters Confidence In PWS Treatment
Portfolio Pulse from Vandana Singh
Soleno Therapeutics Inc (NASDAQ:SLNO) released positive top-line results from a long-term treatment study of DCCR for Prader-Willi syndrome (PWS). Cantor Fitzgerald raised the price target on Soleno Therapeutics from $19 to $35, with an Overweight rating. The analysts believe the PWS market could hold significant appeal for Soleno Therapeutics and that the stock remains undervalued.
September 26, 2023 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive study results and a raised price target by Cantor Fitzgerald could boost Soleno Therapeutics' stock in the short term.
The positive study results for Soleno Therapeutics' DCCR treatment for PWS, along with a raised price target by Cantor Fitzgerald, indicate a favorable outlook for the company. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100